drugset / Trial / NCT01066351

Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery

NCT01066351

Phase 3 Unknown 200 enrolled Thammasat University
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to demonstrate the efficacy of erythropoietin for prevention acute kidney injury in CKD patients undergoing cardiac surgery.

Timeline

Start
2010-01
Primary completion
2011-03
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Beta Erythropoietin Unknown 100 iu/kg Intravenous

Indications